ReviewBiomolecules2026
Renal Aspects of the Apelinergic System: Therapeutic Potential and Mechanisms.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The Apelinergic system (AS) is a crucial endocrine system that plays a vital role in renal physiology and disease. All components of the AS are expressed throughout the kidneys in both humans and rodents. A multitude of studies have consistently shown that the AS exerts a protective effect on the kidneys across a wide spectrum of renal pathologies, encompassing acute kidney injury, chronic kidney disease, diabetic nephropathy, hypertensive kidney injury, cardiorenal syndrome, and renal cell carcinoma. Considering its pivotal role, it shows immense potential as a viable therapeutic target for renal disorders. A deeper mechanistic understanding of the AS will accelerate the rational development of novel therapeutic agents for kidney diseases. In this review, we offer a concise overview of the physiological and pathological roles of the AS in the kidney. Our focus lies on its diuretic effect and its renoprotective action against kidney injury. Enhancing the levels of peripheral Apelin or ELABELA peptides to a certain degree could potentially serve as a promising pharmacological therapeutic strategy for kidney diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.